Armand Butera

Dr. John Botson speaks on the new FDA approval of this combination therapy and its strength regarding increased efficacy and safety.

New data suggests that a third COVID-19 booster might be warranted in children with juvenile idiopathic arthritis.

Furthermore, psoriatic treatment did not appear to significantly reduce COVID-19 vaccine efficacy.

Up to 30% of patients with psoriasis eventually develop inflammatory synovio-entheseal (SE) inflammation.

Though psoriasis often precedes psoriatic arthritis, some studies have shown that the time to transition from psoriasis to PsA had not been fully explained by genetic factors alone.

Dr. Curtis speaks to how the new ACR COVID-19 vaccine guidelines further protect patients with rheumatic disease.

Dr. Mease discusses a recent network meta-analyses that included new phase 3 data on guselkumab.

The analysis also showed guselkumab showed positive joint efficacy among all published advanced therapies approved.

Despite the increasing trend of PRP in knee osteoarthritis, most clinical guidelines do not recommend it due to a lack of evidence on its efficacy.

The biologic has shown promise in the management of both plaque psoriasis and psoriatic arthritis.

Though Dr. Khattri felt the diagnosis of psoriatic arthritis had been “stagnant”, the inclusion of biologic therapies and more has been a welcomed change.

Investigators called for the development of health care system structures to better support the exchanging of resources and information.

The move comes amid delays in FDA approvals for multiple JAK inhibitors for the treatment of rheumatic conditions.

Investigators found no significant differences in the efficacy and safety of the originator or biosimilars in children with juvenile idiopathic arthritis.

Investigators found that patients who were not treated with biologic medications were at a significantly increased risk of developing psoriatic arthritis.

Investigators gathered data from vulnerable populations with rheumatic disease regarding their thoughts and opinions on the COVID-19 virus.

The stigma surrounding gout has contributed to the general unease patients have about their condition.

Research suggests that men and women of all ages in mainland China recorded similar results of untreated osteoporosis and vertebral and clinical fractures, all of which are becoming more prevalent over time.

Dr. LaMoreaux believes that to treat gout in patients with proper medications and therapies, doctors must first establish trust and combat the stigma surrounding this painful form of arthritis.

Dr. Blauvelt speaks on the results of the phase 3b Heads Up study, and the future of upadacitinib and dupilumab in atopic dermatitis management.

Researchers call for greater research on the relationship between PTSD and autoimmune diseases in Medicaid patients after finding a troubling association.

A recent statement by Regeneron noted that chronic spontaneous urticaria is the fifth disease associated with positive Phase 3 results involving the monoclonal antibody.

Researchers record more depressive symptoms in patients with psoriatic arthritis, which they believe incentivizes doctors to utilize screening methods that focus on the mental health of a patient.

Investigators from Turkey show how static foot posture in patients with rheumatic diseases can lead to impairment of physical function due enthesitis.

The newest FDA indication allows for greater distribution to younger but equally vulnerable immunocompromised patients.

Researchers from Texas determined the global prevalence of OSA using 8 unique studies involving patients with rheumatoid arthritis from around the world.

Researchers from France challenge previous reports of the IL-17 inhibitor treatment resulting in an increased risk of inflammatory bowel disease in patients with immune disorders like psoriasis.

Patients with psoriatic arthritis often feel limited in their knowledge on medications and treatments, which investigators said leads to a lack of treatment and increased risk of disability.

New findings show patients with osteoarthritis and rheumatoid arthritis share comorbidities that contribute to an increased likelihood of frailty, especially in older populations.